Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
105.5 USD | -0.40% | -1.69% | -4.19% |
04-29 | Abbott's Dissolving Stent Gets FDA Approval For Arteries Below the Knee | MT |
04-26 | Dexcom's profit beats estimates on strong glucose monitor demand | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.19% | 184B | |
-0.89% | 108B | |
-2.67% | 67.82B | |
+3.86% | 51.05B | |
+9.05% | 44.67B | |
+3.40% | 41.78B | |
+1.99% | 26.78B | |
+3.84% | 26.59B | |
+15.23% | 25.86B | |
-1.45% | 25.03B |
- Stock Market
- Equities
- ABT Stock
- News Abbott Laboratories
- Raymond James Adjusts Abbott Laboratories' Price Target to $150 From $134, Keeps Outperform Rating